Breast cancer has not been traditionally been considered a solid tumor type amendable to immune approaches. Correlative and biomarker data strongly suggest that immune infiltrates are positively prognostic hence raising the hypothesis that some breast cancer subtypes may be more immunogenic than others. Early phase trials evaluating checkpoint blockade in advanced breast cancer are still not complete nor definitive, but early data suggests that those who achieve a response can have durable disease control. Identifying who may respond and the best biomarker is still an area of ongoing and active investigation. In this presentation I will go through correlative, preclinical and status of current and future directions of clinical and biomarker data in the immunotherapy field related to breast cancer.